Clinical trials
Drug Use Disorders clinical trials
Below are recruiting drug use disorders clinical trials, each written for real people, not researchers. We’re tracking 278 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07148843RecruitingPhase 2/Phase 3
CBD for alcohol withdrawal and cravings
This study tests whether adding CBD (a cannabis compound that doesn't get you high) to usual care can help reduce alcohol withdrawal symptoms and cravings. It may offer a new way to support people trying to cut down or stop drinking.
Baltimore, MarylandAges 21–65 - NCT07118618RecruitingPhase 2
Probenecid for alcohol cravings and drinking
This study tests if the medication probenecid can help reduce cravings for alcohol and the amount you drink. It is for people who drink heavily and have moderate to severe alcohol use disorder.
Providence, Rhode IslandAges 18 years+ - NCT07086014Recruiting
Brain response to methamphetamine cues in men
This study uses brain scans to see how men with methamphetamine use disorder react to images or reminders of the drug. It aims to understand cravings and brain activity, which could help improve treatments.
New York, New YorkAges 18–60 - NCT07091877Recruiting
Cocaine use and brain response study
This study looks at how cravings for cocaine change over time in people who have recently stopped using. Researchers will measure brain activity to understand this process better.
New York, New YorkAges 18–65 - NCT07086794RecruitingEarly Phase 1
Testing if pentoxifylline helps reduce cocaine use
This study tests whether a medication called pentoxifylline can reduce cocaine use in people who smoke or inject cocaine but aren't ready to stop. You'll receive either pentoxifylline or a placebo to see if it helps control cravings or use.
Lexington, KentuckyAges 18–55 - NCT07046819RecruitingPhase 2
Tirzepatide for liver disease linked to alcohol use
This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.
Bethesda, MarylandAges 21–100 - NCT07027839RecruitingPhase 1
Alcohol effects on brain imaging for phosphodiesterase
This study uses PET scans to see how alcohol affects a protein in the brain called PDE4B. It may help explain how alcohol works in the body.
Bethesda, MarylandAges 21–70 - NCT06989853RecruitingEarly Phase 1
Testing troriluzole for methamphetamine use disorder
This study tests whether a medication called troriluzole can help people who use methamphetamine. If you have methamphetamine use disorder and are not seeking treatment right now, this study may be an option for you.
Lexington, KentuckyAges 18–55 - NCT06949826RecruitingPhase 4
Buprenorphine for pain after ankle fracture surgery
This trial tests if buprenorphine, a non-opioid pain medicine, works well for people who have not used opioids before. After ankle fracture surgery, you would get buprenorphine instead of stronger opioids to see if it controls pain just as well with fewer side effects.
St Louis, MissouriAges 18 years+ - NCT06940674RecruitingPhase 3
CBD plus opioid treatment for recovery
This study tests whether adding cannabidiol (CBD) to your usual methadone or buprenorphine treatment helps you recover from opioid use disorder. If you're already in stable treatment with those medications, the trial aims to see if CBD can improve your outcomes.
New York, New YorkAges 18–65 - NCT06899594RecruitingEarly Phase 1
Psilocybin for quitting methamphetamine
This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.
Shreveport, LouisianaAges 25–65 - NCT06877858RecruitingPhase 1
MethaLoad dose-finding study for opioid use disorder
This study tests a new way to start methadone treatment (called 'MethaLoad') for people with opioid use disorder who have used fentanyl. If you qualify, you will receive methadone to help manage withdrawal and reduce cravings, and the doctors will closely monitor your safety and response.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06853873Enrolling by invitation
Alcohol counseling for safer pregnancies
This trial tests a counseling program to help pregnant women reduce risky alcohol use. The program is designed to support women in making healthier choices for themselves and their baby.
Cape TownAges 18 years+ - NCT06810310RecruitingPhase 2
Psilocybin for motivation in opioid use disorder
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Philadelphia, PennsylvaniaAges 18–60 - NCT06786325RecruitingPhase 2
Psilocybin treatment study for opioid use disorder
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Philadelphia, PennsylvaniaAges 18–60 - NCT06774248Recruiting
Teen opioid recovery support program with medication
This study tests a program called YORS that helps teens with opioid use disorder stick with their medication. It involves you and a support person (like a parent) working together with the study team to stay on track.
Baltimore, MarylandAges 13–21 - NCT06639464RecruitingPhase 2
Semaglutide for improving opioid recovery outcomes
This study tests whether semaglutide (a medication used for weight management) can help people on buprenorphine or methadone reduce their opioid use. If it works, it could provide additional support during recovery.
Boston, MassachusettsAges 18 years+ - NCT06617312RecruitingPhase 2
Cytisinicline and brain response to smoking cues
This study tests how a medicine called cytisinicline (similar to a plant-based stop-smoking aid) affects brain activity when you see or think about smoking. It may help researchers understand how the medicine works, even if you aren't ready to quit right now.
Los Angeles, CaliforniaAges 18–65 - NCT06582888RecruitingEarly Phase 1
VR attention test for smoking cravings
This study tests whether a virtual reality (VR) program can measure how your brain pays attention to smoking cues. It also involves taking a medication called varenicline (Chantix) to see if it reduces cravings. You may be eligible if you are a daily smoker, have been smoking for at least 3 years, and are not ready to quit in the next month.
San Diego, CaliforniaAges 22 years+ - NCT06544291RecruitingPhase 2
THC and CBD for pain and opioid use disorder
This study tests whether a combination of THC and CBD can help people who have both opioid use disorder and chronic low back pain. You would need to be on a stable dose of methadone and have used cannabis at least once in your life.
New Haven, ConnecticutAges 18–65 - NCT06494904RecruitingPhase 3
Standard vs. High Dose Buprenorphine in the ER
This study compares a higher dose of buprenorphine (a medicine that helps stop opioid cravings and withdrawal) to the usual dose, given in the emergency department. It aims to see if the higher dose works better to start treatment for opioid use disorder.
Oakland, CaliforniaAges 18–65 - NCT06489782Recruiting
New approach to test alcohol use disorder medications
This study tests a new way to quickly screen medications for alcohol use disorder (AUD). You will have lab sessions where your drinking is monitored to see how different medicines affect your alcohol use.
New Haven, ConnecticutAges 21–65 - NCT06494891RecruitingPhase 2
Understanding motivation for IV alcohol drinking
This study looks at why people with alcohol use disorder choose to drink alcohol given through an IV. The goal is to better understand the motivation behind drinking, which could help improve treatments.
Los Angeles, CaliforniaAges 21–65 - NCT06432465Recruiting
Brain stimulation to help prevent opioid relapse
This study uses a type of brain stimulation called tDCS (transcranial direct current stimulation) to see if it can help people who have recently started medication for opioid dependence (buprenorphine or methadone) stay on track and avoid relapse. The treatment is non-invasive and involves a mild electrical current applied to the scalp.
Providence, Rhode IslandAges 21–60
Hear when a new Drug Use Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for drug use disorders?
- Yes. Clin2 currently lists 278 recruiting drug use disorders studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a drug use disorders trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a drug use disorders trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.